Axial spondyloarthritis: Patients are benefit from certolizumab pegol
28
Jun
Researchers are reporting that early rapid improvements in the signs and symptoms of axial spondyloarthritis in patients treated with certolizumab pegol are maintained at 4 years. Axial spondyloarthritis is characterized by inflammation of the sacroiliac joins and spine, which results … Read More »